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The epithelial–mesenchymal transition (EMT) describes a reversible switch from an
epithelial-like to a mesenchymal-like phenotype. It is essential for the development of the
normal epithelium and also contributes to the invasive properties of carcinomas. At the
molecular level, the EMT transition is characterized by a series of coordinated changes
including downregulation of the junctional protein E-cadherin (CDH1), up-regulation
of transcriptional repressors of E-cadherin such as Snail (SNAI1) and Slug (SNAI2),
and up-regulation of N-cadherin. We wished to determine whether cultured normal
melanocytes and melanoma cell lines, which are derived from the neural crest, showed
signs of a similarly coordinated phenotypic switch. We investigated normal melanocytes
and 25 cell lines derived from New Zealand patients with metastatic melanoma. Most
lines had been previously genotyped for common mutations such as BRAF, NRAS, PIK3CA
(phosphatidylinositol-3-kinase), TP53 (p53), and CDKN2A (p16). Expression of E-cadherin,
N-cadherin, microphthalmia-associated transcription factor (MITF), Snail, Slug, Axl, p53,
and Hdm2 was compared by western blotting. Normal melanocytes expressed each of
these proteins except for Snail, while normal melanocytes and almost every melanoma line
expressed Slug. Expression of individual markers among different melanoma lines varied
from high to low or undetectable. Quantitation of western blots showed that expression
of MITF-M, the melanocyte-speciﬁc isoform of MITF, was positively related to that of
E-cadherin but inversely related to that of N-cadherin and Axl. There was also no apparent
relationship between expression of any particular marker and the presence of BRAF,
NRAS, PIK3CA,TP53, or CDKN2A mutations. The results suggest that melanomas do not
show the classical epithelial and mesenchymal phenotypes but rather display either high
E-cadherin/high MITF-M expression on one hand, or high N-cadherin/high Axl expression
on the other. These may correspond to differentiated and invasive phenotypes in vivo.
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INTRODUCTION
The epithelial–mesenchymal transition (EMT) describes a
reversible phenotypic change in epithelial cells that is essential
for embryogenesis and wound healing in normal tissues. It is
characterized by the loss of functional E-cadherin containing junc-
tions and loss of cell polarity, and is particularly associated with
the expression of zinc-ﬁnger transcription factors Snail (SNAI1)
and Slug (SNAI2), as well as of ZEB1 (zinc-ﬁnger E-box-binding
homeobox 1), ZEB2, FoxC2 (forkhead box protein C2), and
TWIST (Lim and Thiery, 2012). Expression of the intermediate
ﬁlament protein vimentin appears to be upregulated by Slug in
cells undergoing EMT; vimentin thenup-regulates theAxl tyrosine
kinase, which contributes to changes in cytoskeletal architecture
and migratory potential (Ivaska, 2011). These changes in adhe-
sion proteins cause cells to change to a morphology resembling
that of mesenchymal cells and to a functional change toward
migration, invasion, and resistance to apoptosis. Evidence for
EMT has also been found in carcinomas, leading to the pro-
posal that it is involved in both invasion and metastasis (Lim and
Thiery, 2012).
Melanocytes differ from epithelial cells in having their origin in
the neural crest, a collection of multipotent and migratory cells in
the vertebrate embryo that is also important for the development
of cartilage, bone, neurons, glia, and smooth muscle. Although
the term EMT arose from studies in epithelial tissues, it has been
applied to a variety of developmental tissues including migra-
tory neural crest cells that are the precursors of melanocytes. Slug
appears to be essential for precursor migration and melanocyte
development in mammals; Slug knockout mice exhibit some
features of theWaardenburg syndrome in humans,which is associ-
ated with hypopigmentation and hearing loss (Shirley et al., 2012),
while loss of one Slug allele in humans is associated with piebald-
ism (Sanchez-Martin et al., 2003). Expression of Slug is closely
related to that of microphthalmia-associated transcription factor
(MITF; Sanchez-Martin et al., 2002), which in turn is essential
for expression of proteins mediating the production of melanin
by mature melanocytes. Such cells also express E-cadherin, pre-
sumably allowing both functional interaction with E-cadherin
expressed on keratinocytes (Kuphal and Bosserhoff, 2012) and
transfer of melanosomes.
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Melanoma cells differ from melanocytes by acquiring inva-
sive and/or metastatic properties, depending on the state of the
melanoma (Orgaz and Sanz-Moreno, 2013). It has been sug-
gested that the invasive and metastatic potential of melanoma cells
reﬂects their ability to undergo EMT-like reversible phenotypic
changes (Shirley et al., 2012). Histological studies of melanoma
show frequent expression of Slug, E-cadherin, and MITF but also
considerable heterogeneity of expression of these proteins among
individual cells from the same specimen (Shirley et al., 2012). The
aim of this study was to assess the degree of coordinated expres-
sion of EMT-associated markers in a series of low passage human
melanoma cell lines, comparing expression with that of cultured
normal melanocytes. We utilized a series of melanoma lines that
were originally derived fromNewZealand patients withmetastatic
melanoma to assess responses to radiotherapy and chemother-
apy (Marshall et al., 1992, 1994; Kim et al., 2012). Many of these
cell lines have been characterized for genetic mutations in BRAF,
NRAS, PIK3CA (phosphatidylinositol-3-kinase), TP53 (p53), and
CDKN2A (p16) genes (Parmar et al., 2000; Charters et al., 2011).
In this study, we have grown 25 of these melanoma cell lines, char-
acterized their expression of E-cadherin, N-cadherin, Snail, Slug,
Axl, p53, Hdm2, and MITF, examining the relationship between
protein expression and common genetic aberrations.
MATERIALS AND METHODS
CULTURE OF MELANOMA CELLS AND MELANOCYTES
The 25 New Zealand melanoma (NZM) cell lines were gener-
ated from surgical samples of metastatic melanoma as previously
described (Marshall et al., 1994; Kim et al., 2012). Written con-
sent was obtained from all patients under Auckland Area Health
Board Ethics Committee guidelines. NZM cell lines were grown
under low oxygen conditions (5% O2) in order to mimic physio-
logically low oxygen levels in tumors. NZM lines were grown in
α-modiﬁed minimal essential medium (αMEM; Invitrogen, USA)
supplemented with insulin (5 μg/mL), transferrin (5 μg/mL), and
sodium selenite (5 ng/mL; Roche Applied Sciences, Germany),
100 U/mL of penicillin, 100 μg/mL of streptomycin (PS), and
5% fetal bovine serum (FBS). Human primary melanocytes were
purchased from Invitrogen and grown in light sensitive Medium
254 supplemented with human melanocyte growth supplement
(HMGS-2; Invitrogen) and PS.Humanmelanocytes were cultured
in an atmosphere of 5% CO2 in air at 37◦C. Genetic analyses of
BRAF,NRAS,TP53,CDKN2A, andPIK3CA inNZMcell lines were
carriedout. Selectedmelanomacell lineswere sequenced formuta-
tions in BRAF, NRAS, and PIK3CA as previously described (Kim
et al., 2012). Sequencing for mutations in the TP53 and CDKN2A
genes has been previously described (Parmar et al., 2000; Charters
et al., 2011).
WESTERN BLOTTING
After NZM cells were grown to about 80% conﬂuence, they
were washed in ice-cold phosphate buffered saline (PBS), lysed in
radioimmunoprecipitation assay buffer and prepared for western
blotting as previously described (Kimet al., 2009). Antibodies used
were speciﬁc for the following epitopes: E-cadherin, N-Cadherin,
Snail, Slug, and Axl were from Cell Signaling Technology; MITF
was from Abcam; and p53, HDM2, and β-actin were from Santa
Cruz. Western blots were quantiﬁed using Image J software and
expressed as a ratio to β-actin.
STATISTICAL ANALYSIS
Spearman’s rank correlation coefﬁcient (rs) and statistical sig-
niﬁcance (p) were calculated using standard methods (SPSS).
Values of p < 0.05 were considered to be statistically signiﬁcant.
Correlation plots were also ﬁtted with best-ﬁt hyperbolae.
RESULTS
EXPRESSION OF E-CADHERIN, N-CADHERIN, Snail, and Slug
Since EMT is normally associated with loss of E-cadherin expres-
sion and gain of N-cadherin, we ﬁrst measured cadherin expres-
sion. Normal melanocytes expressed both proteins and about half
of the lines (NZM11, NZM85, NZM86, NZM9, NZM17, NZM26,
NZM40, NZM50, NZM59, NZM4, and NZM82) showed moder-
ate to strong N-cadherin expression but no E-cadherin expression.
The other lines all expressed E-cadherin except for NZM22, which
expressed neither (Figure 1A). When we quantiﬁed the west-
ern blots and normalized it to β-actin expression (Figure 1B),
we observed an inverse correlation between E-cadherin and N-
cadherin expression (Figure 2A). Quantiﬁcation and statistical
analysis showed a signiﬁcant negative correlation between E-
cadherin and N-cadherin expression (rs = −0.578; p = 0.002).
Slug, the putative transcriptional repressor for E-cadherin, was
expressed in normal melanocytes as well as in all lines with
the exception of NZM17. The relative expression of E-cadherin
and Snail suggested an inverse correlation (Figure 1A). However,
quantiﬁcation (Figure 2B) showed this to be not statistically sig-
niﬁcant (rs =−0.272; p= 0.18).We also testedwhether expression
of these markers was associated with any of the mutations shown
in Table 1, but no clear relationship was found.
EXPRESSION OF Axl, MITF, p53, and Hdm2
It has been previously reported that EMT is associated with
increased Axl expression (Gjerdrum et al., 2010) and reduced
MITF expression (Sensi et al., 2011). We measured Axl expres-
sion and found it only in a proportion of cell lines (Figure 3A).
Although it appeared from western blots that Axl expression was
inversely correlated to E-cadherin expression, quantitation failed
to show signiﬁcance (rs = −0.108). MITF has several isoforms
(Yasumoto et al., 1998), and the A and M isoforms are expressed
in the melanocyte lineage (Goding, 2000) with the M isoform
having differentially spliced variants (Hodgkinson et al., 1993; Ste-
ingrimsson et al., 1994; Selzer et al., 2002). Both MITF-A and
MITF-M were found in the cell lines (Figure 3), with the MITF-
M isoform appearing as two differentially spliced variants. We
quantiﬁed blots for MITF isoforms (Figure 3B) and observed a
statistically signiﬁcant inverse relationship (p = 0.006) between
MITF-M expression and Axl expression (Figure 4A). Several cell
lines (NZM49, NZM22, and NZM7), as well as melanocytes,
expressed both Axl and MITF. Interestingly, NZM49 and NZM22,
which express both MITF and Axl, expressed more MITF-A
than other cell lines. Furthermore, there was a signiﬁcant neg-
ative correlation between MITF-M and N-cadherin expression
(rs = −0.562; p = 0.007; Figure 4B) and a signiﬁcant positive cor-
relation between MITF-M expression and E-cadherin (rs = 0.514;
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FIGURE 1 | (A)Western blots of whole-cell extracts derived from cultures of
normal melanocytes and of a number of melanoma lines, indicating
expression of N-cadherin, E-cadherin, Snail, and Slug. The numbers indicate
the identities of members of the New Zealand melanoma collection (e.g.,
3 = NZM3); Mel indicates data for normal melanocytes. The western blot
shown is representative of three independent repeats. (B)Western blot
quantiﬁcation of E-cadherin, N-cadherin, and Snail as ratios to β-actin loading
controls. Bars show SEM.
FIGURE 2 | Relationship between expression of (A) N-cadherin and E-cadherin, and (B) E-cadherin and Snail normalized to β-actin expression.The
lines indicate best-ﬁt hyperbolae.
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Table 1 | Genetic status of the melanoma lines used in this study.
NZM BRAF NRAS TP53 CDKN2A PIK3CA
3 V600E Deletion
4 V600E 241S/P
7 V600E 241S/P/WT
9 179C/T Deletion
11 V600E Deletion
12 V600E
13 Deletion
15 Q61K
17 Q61K 241S/T
20 V600E Deletion
22 241S/T/W
23
26 V600E 136A/G
28 241S/T/WT + 159a/v
39 213A/G Deletion
40 Q61H Del 249-253 H1047R
48 Q61K
49 V600E Deletion
50 R280T
59 Silent T/G Deletion
71
82
85
86
100
p = 0.007; not shown). Since it has been reported that loss of p53
expression is associated with EMT (Gadea et al., 2007), we also
measured expression of p53 and of Hdm2, a protein closely asso-
ciated with p53 degradation (Araki et al., 2010). However, there
was no obvious relationship between expression of either p53 or
Hdm2 and that of other EMT markers (Figure 3A). As MITF has
been noted to be one of the key molecular switches that determine
switching of different cell progeny (Cheli et al., 2011), we also
stained for MITF to observe expression in individual cells within
the same cell line. Interestingly, in NZM86 and NZM40 (two cell
lines that express very low MITF as determined by western blot-
ting) we observed individual cells that expressed detectable levels
of MITF (Figure 5) scattered amongst low MITF expressing cells.
DISCUSSION
The analysis of this series of early passage human melanoma
lines has shown them to be highly heterogeneous not only
with respect to expression of proteins directly associated with
EMT such as E-cadherin, Snail, Slug, and Axl (Figure 1) but
also with respect to expression of proteins that are more indi-
rectly associated with EMT, such as MITF and p53 (Figure 3).
Melanoma lines (with one exception) and normal melanocytes,
expressed Slug. Other markers are generally strongly expressed
in some lines but not others. Among the melanoma lines, we
found that expression of MITF-M, the melanocyte-speciﬁc iso-
form of MITF, was positively related to that of E-cadherin but
inversely related to that of N-cadherin and Axl (Figures 4A,B).
A possible interpretation of the results is that melanoma lines
show mesenchymal properties overall, but that individual lines
vary between a high E-cadherin/high MITF-M expression and a
high N-cadherin/high Axl expression phenotype. Cultured nor-
mal melanocytes show an intermediate phenotype, expressing all
markers.
The results agree with an earlier study reporting that Axl-
positive melanoma cells do not express MITF (Sensi et al.,
2011). They also support a previous study that used a series
of NZM melanoma cell lines to identify a gene expression sig-
nature that distinguished two phenotypes differing in their in
vitro invasive potential (Jeffs et al., 2009). Although the cell
lines used in that study overlap only partially with the lines
used in the present study it is evident that the six lines with
the “non-invasive” signature (NZM3, NZM4, NZM7, NZM12,
NZM15, and NZM20) expressed MITF but little or no Axl while
four with the “invasive” signature (NZM9, NZM11, NZM22,
and NZM40) expressed no MITF but often expressed Axl
(Figure 3).
One of the important questions posed in this study is whether
the pattern of expression of proteins in the EMT pathway is
related to genetic mutation. A detailed analysis of the muta-
tional status of the melanoma lines will be reported elsewhere
in this issue (Stones et al., 2013) but with the available data shown
in Table 1, we have been unable to detect any signiﬁcant rela-
tionship between expression of proteins shown in Figures 1 and
3 and the mutational status of BRAF, NRAS, TP53, CDKN2A,
or PIK3CA. These results echo those obtained from a study
on the utilization of enzymes in the PI3K–PKB (phosphoinosi-
tide 3-kinase–protein kinase B), MEK–ERK (mitogen-activated
protein kinase kinase–extracellular signal-regulated kinase), and
mTOR–p70S6K (mammalian target of rapamycin–p70 ribosomal
S6 kinase) signaling pathways. As determined by phosphorylation
of signaling components, phosphorylation varied widely across a
series of cell lines but did not directly reﬂect the PIK3CA, PTEN,
NRAS, or BRAF mutational status of genes of these lines (Kim
et al., 2012). A feature of the results is that individual melanoma
lines vary enormously in their expression of particular proteins.
This extends a previous study showing a large amount of het-
erogeneity in expression of MITF and the melanocyte lineage
proteins PAX3 across a series of NZM lines, with cellular protein
levels varying by 15-fold and more than 100-fold, respectively (He
et al., 2011). Phenotypic switching has previously been suggested
to explain differences in transcription signatures that correspond
to different cellular phenotypes (Hoek et al., 2008; Hoek and
Goding, 2010) and could account for the differences in protein
expression.
Recently, MITF has been suggested to be crucial in determining
whether melanoma cells proliferate (melanoma initiating cells)
or change to accommodate a more invasive phenotype (Carreira
et al., 2006; Hoek and Goding, 2010; Cheli et al., 2011); this has
formed the basis for the hypothesis discussed separately in this
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FIGURE 3 | (A)Western blots of extracts from cultures of normal
melanocytes and of a number melanoma lines, indicating expression of
MITF-M (bottom two bands), MITF-A (top band), Axl, p53, and Hdm2. The
numbers indicate the identities of members of the New Zealand melanoma
collection; Mel indicates data for normal melanocytes. The western blot
shown is representative of three independent repeats. (B)Western blot
quantiﬁcation of MITF-M and Axl as ratios to β-actin loading controls. Bars
show SEM.
FIGURE 4 | Relationship between expression of (A) MITF-M andAxl, and (B) MITF-M and N-cadherin normalized to β-actin expression.The lines
indicate best-ﬁt hyperbolae.
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FIGURE 5 | Immunofluorescent images of NZM40 and NZM86 stained for MITF (green) and for DNA (diaminophenylindole: blue). Scale bars on the
merged image indicate 50 μm.
issue (Eccles et al., unpublished). The mechanistic basis of such
switching has not yet been elucidated but the concept is consis-
tent with evidence that melanomas cells do not have a deﬁned
hierarchical organization with stem cells at one end and differen-
tiated cells at the other (Quintana et al., 2008). Rather, each cell
in a population may have a certain probability of switching to or
from a phenotype with stem cell characteristics. There are specu-
lations as to what could induce or decrease MITF activity (Strub
et al., 2011) and determine the invasiveness or the stemness of
the melanoma cells in response to hypoxia (Cheli et al., 2012) or to
other factors in the tumor microenvironment (Li et al., 2003). One
interesting observation is that even though NZM40 and NZM86
show low MITF expression by western blotting, we clearly see
by microscopy that some cells highly express MITF (Figure 5),
which is evidence of a heterogeneous population of cells
(Quintana et al., 2010).
Histological studies on in vivo human melanoma tissue have
shown considerable heterogeneity by individual cells in expres-
sion of markers associated with EMT (Shirley et al., 2012) and this
is consistent with the in vitro histological data shown in Figure 5.
It is possible that melanoma tissue in vivo shows even greater
phenotypic diversity than the derived cell lines. Thus, as shown
diagrammatically in Figure 6, the in vivo, population develops,
by phenotypic switching, a diverse population with individual
cells exhibiting a high E-cadherin/high MITF-M expression on
one hand or a high N-cadherin/high Axl expression on the other.
Melanomas in vivo generally have cell cycle times of approximately
1 week, while derived cell lines have cell cycle times of 1–2 days
(Baguley, 2011). Development of cell lines thus exerts a strong
selective pressure for outgrowth of more rapidly cycling cells and
FIGURE 6 | Possible model for the generation of melanoma cell lines.
Phenotypic switching in vivo generates a highly heterogeneous population
of cells that vary in expression of proteins such as E-cadherin, N-cadherin,
Axl, and M-MITF. Derivation of a cell line, by selecting for rapid proliferation,
may select for an individual phenotype.
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may tend to select one of these phenotypes. Thus, melanoma
tissue may be characterized as a mixture of phenotypes, some
expressing high MITF-M and E-cadherin with more differentiated
non-invasive behavior, and others expressing high N-cadherin,
Slug, and Axl and with a more invasive behavior.
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